It has been debated for years whether genetic, extrinsic factors  (i.e., exposure to pathogen infection and environmental agents contributes to tumorigenesis) or intrinsic factors  (‘bad luck hypothesis’ – random error mutations during DNA replication in a small fraction of stem cells may be implicated in two-thirds of variation of cancer risk in 25 cancer types) contribute to tumorigenesis and metastasis. Both ‘bad luck’ and ‘extrinsic factor’ hypotheses are dominate in the field. Although both hypotheses disagree each other in terms of intrinsic and extrinsic factors for contributing tumorigenesis, they agree that heredity plays a minimal role in tumorigenesis. Indeed, from cancer cell point of view, family history and a handful of known cancer genes may only explain <5% of cancer population. However, both hypotheses are cancer cell-centered and ignored immune system.
From a systems point of view, we have proposed that genetic variants of the pre-existing genome (i.e., in-born genome or germline genome) could work together with somatic mutations to induce a transformation of a normal cell into a cancer cell, cancer progression and metastasis . Meanwhile, immune system combats cancer cells as well. Thus, in-born genomes and immune system could contribute significantly to tumorigenesis and metastasis. In this study, we set out to test a hypothesis that in-born genomes and immune system play an important role in metastasis. Thus far, none of a single gene bearing pathogenic germline variants is able to predict survival for the whole patient population of any cancer type. We applied our recently developed algorithm, eTumorMetastasis which enables to construct predictive models based on genome-wide mutations, to ER+ breast cancer using genome-wide pathogenic germline variants. We showed that genes bearing pathogenic germline variants significantly distinguished recurred and non-recurred patients in two ER+ breast cancer independent cohorts (n = 200 and 295) . These results suggest that in-born genomes contribute to tumorigenesis and metastasis much more than previously expected. Further analyses of gene signatures which are able to predict metastases suggest that pathogenic germline variants could shape metastasis via regulating tumor-infiltrating leukocytes (TILs), for example, pathogenic germline variants predicted high-risk tumors contain significantly less CD8+ T, dendritic cells (DC), NK (natural killer) and B cells than low-risk tumors predicted by the pathogenic germline variants. These results suggest that inborn genomes could contribute tumor metastasis by modulating TILs. Because germline genomic information can be obtained vis sequencing of blood samples, practically, this study opens a new window for a non-invasive means for predicting cancer prognosis.
Along the same line, we showed that the number of inherited pathogenic germline variants in NK cells is positively correlated with cancer risk and negatively correlated with the fractions of TILs and patient survival . These two studies strongly support our hypothesis that inherited pathogenic germline variants associated with immune system play a significant role in tumorigenesis and metastasis. In summary, from the view of cancer cell, hereditary plays a minimal role in tumorigenesis, however, from the view of immune system, hereditary plays a critical role in both tumorigenesis and metastasis.
 Wu et al., Substantial contribution of extrinsic risk factors to cancer development. Nature, 529:43, 2016
 Tomasetti et al., Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention, Science, 355:1330, 2017
 Edwin Wang et al., Predictive Genomics: A cancer hallmark network framework for predicting tumor clinical phenotypes using genome sequencing data, Seminars in Cancer Biology, 30:4-12, 2015
 Milanese et al., Germline variants associated with leukocyte-genes predict tumor recurrence in breast cancer patients, npj Precision Oncology, 3:28, 2019
 Xu et al., Association of germline variants in natural killer cells with tumor immune microenvironment subtypes, tumor-infiltrating lymphocytes, immunotherapy response, clinical outcomes, and cancer risk, JAMA Network Open, 2:e199292, 2019